These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Extra-pyramidal syndrome caused by neuroleptics]. Lambert PA Encephale; 1973; 62(1):78-105. PubMed ID: 4718697 [No Abstract] [Full Text] [Related]
3. [Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome]. Kamianov IM; Kupisk AG; Katsen IZ Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(8):1218-23. PubMed ID: 4149581 [No Abstract] [Full Text] [Related]
4. [Neurologic and psychic complications in treatment with neuroleptics]. Gerlach J Ugeskr Laeger; 1976 Jun; 138(27):1650-3. PubMed ID: 951778 [No Abstract] [Full Text] [Related]
6. [Incidents and accidents during therapy with long-acting neuroleptics]. Escande M; Vasquez Villareal S; Gayral L Ann Med Psychol (Paris); 1974 Jan; 1(1):112-20. PubMed ID: 4210849 [No Abstract] [Full Text] [Related]
7. [Somatic disorders during long-term drug treatment of schizophrenic patients]. vom Brocke I Internist (Berl); 1974 May; 15(5):268-70. PubMed ID: 4213663 [No Abstract] [Full Text] [Related]
8. Neutralization of extrapyramidal side-effects with Methixene. Maller O; Heller S Dis Nerv Syst; 1971 Jun; 32(6):409-15. PubMed ID: 5570695 [No Abstract] [Full Text] [Related]
9. Evolutionary origin of extrapyramidal disorders in drug-treated mental patients, its significance, and the role of neuromelanin. Forrest FM Adv Biochem Psychopharmacol; 1974; 9(0):255-68. PubMed ID: 4151764 [No Abstract] [Full Text] [Related]
10. Drug-induced Parkinson-like syndrome. Va Med Mon (1918); 1968 Dec; 95(12):746-50 passim. PubMed ID: 5725399 [No Abstract] [Full Text] [Related]
11. [On the mode of action and the question of central organic late damages of continuous neuroleptic treatment]. Haddenbrock S Nervenarzt; 1966 May; 37(5):199-203. PubMed ID: 5298253 [No Abstract] [Full Text] [Related]
12. Behavioral, biochemical, and pharmacological effects of chronic dosage of phenothiazine tranquilizers in rats. Maickel RP; Braunstein MC; McGlynn M; Snodgrass WR; Webb RW Adv Biochem Psychopharmacol; 1974; 9(0):593-602. PubMed ID: 4836224 [No Abstract] [Full Text] [Related]
13. Movement disorders secondary to drugs. Paulson GW Ohio State Med J; 1973 Sep; 69(9):685-6. PubMed ID: 4746475 [No Abstract] [Full Text] [Related]
14. Adverse clinical side effects of levodopa therapy. Barbeau A; Mars H; Gillo-Joffroy L Contemp Neurol Ser; 1971; 8():203-37. PubMed ID: 5293414 [No Abstract] [Full Text] [Related]